269 related articles for article (PubMed ID: 17509751)
1. The effect of levodopa on respiration and word intelligibility in people with advanced Parkinson's disease.
De Letter M; Santens P; De Bodt M; Van Maele G; Van Borsel J; Boon P
Clin Neurol Neurosurg; 2007 Jul; 109(6):495-500. PubMed ID: 17509751
[TBL] [Abstract][Full Text] [Related]
2. The effects of levodopa on word intelligibility in Parkinson's disease.
De Letter M; Santens P; Van Borsel J
J Commun Disord; 2005; 38(3):187-96. PubMed ID: 15748723
[TBL] [Abstract][Full Text] [Related]
3. Levodopa-induced modifications of prosody and comprehensibility in advanced Parkinson's disease as perceived by professional listeners.
De Letter M; Santens P; Estercam I; Van Maele G; De Bodt M; Boon P; Van Borsel J
Clin Linguist Phon; 2007 Oct; 21(10):783-91. PubMed ID: 17882694
[TBL] [Abstract][Full Text] [Related]
4. Levodopa-induced alterations in speech rate in advanced Parkinson's disease.
De Letter M; Santens P; De Bodt M; Boon P; Van Borsel J
Acta Neurol Belg; 2006 Mar; 106(1):19-22. PubMed ID: 16776432
[TBL] [Abstract][Full Text] [Related]
5. Effects of subthalamic nucleus stimulation on parkinsonian dysarthria and speech intelligibility.
Rousseaux M; Krystkowiak P; Kozlowski O; Ozsancak C; Blond S; Destée A
J Neurol; 2004 Mar; 251(3):327-34. PubMed ID: 15015014
[TBL] [Abstract][Full Text] [Related]
6. Pulmonary functions in Parkinson's disease.
Sathyaprabha TN; Kapavarapu PK; Pall PK; Thennarasu K; Raju TR
Indian J Chest Dis Allied Sci; 2005; 47(4):251-7. PubMed ID: 16255396
[TBL] [Abstract][Full Text] [Related]
7. Stimulation of the pedunculopontine nucleus area in Parkinson's disease: effects on speech and intelligibility.
Pinto S; Ferraye M; Espesser R; Fraix V; Maillet A; Guirchoum J; Layani-Zemour D; Ghio A; Chabardès S; Pollak P; Debû B
Brain; 2014 Oct; 137(Pt 10):2759-72. PubMed ID: 25080284
[TBL] [Abstract][Full Text] [Related]
8. Sequential changes in motor speech across a levodopa cycle in advanced Parkinson's disease.
De Letter M; Van Borsel J; Boon P; De Bodt M; Dhooge I; Santens P
Int J Speech Lang Pathol; 2010 Oct; 12(5):405-13. PubMed ID: 20602581
[TBL] [Abstract][Full Text] [Related]
9. Rate and loudness manipulations in dysarthria: acoustic and perceptual findings.
Tjaden K; Wilding GE
J Speech Lang Hear Res; 2004 Aug; 47(4):766-83. PubMed ID: 15324285
[TBL] [Abstract][Full Text] [Related]
10. Effects of bilateral subthalamic nucleus stimulation and medication on parkinsonian speech impairment.
D'Alatri L; Paludetti G; Contarino MF; Galla S; Marchese MR; Bentivoglio AR
J Voice; 2008 May; 22(3):365-72. PubMed ID: 17368837
[TBL] [Abstract][Full Text] [Related]
11. [Speech and voice disorders in Parkinson's disease].
Martnez-Sánchez F
Rev Neurol; 2010 Nov; 51(9):542-50. PubMed ID: 20979034
[TBL] [Abstract][Full Text] [Related]
12. Influence of listening conditions and listener characteristics on intelligibility of dysarthric speech.
Pennington L; Miller N
Clin Linguist Phon; 2007 May; 21(5):393-403. PubMed ID: 17468997
[TBL] [Abstract][Full Text] [Related]
13. Effect of speech task on intelligibility in dysarthria: a case study of Parkinson's disease.
Kempler D; Van Lancker D
Brain Lang; 2002 Mar; 80(3):449-64. PubMed ID: 11896652
[TBL] [Abstract][Full Text] [Related]
14. The effects of levodopa on tongue strength and endurance in patients with Parkinson's disease.
De Letter M; Santens P; Van Borsel J
Acta Neurol Belg; 2003 Mar; 103(1):35-8. PubMed ID: 12704981
[TBL] [Abstract][Full Text] [Related]
15. Pattern of subclinical pulmonary dysfunctions in Parkinson's disease and the effect of levodopa.
Pal PK; Sathyaprabha TN; Tuhina P; Thennarasu K
Mov Disord; 2007 Feb; 22(3):420-4. PubMed ID: 17230476
[TBL] [Abstract][Full Text] [Related]
16. Rapid eye movement sleep behavior disorder preceding Parkinson's disease with therapeutic response to levodopa.
Tan A; Salgado M; Fahn S
Mov Disord; 1996 Mar; 11(2):214-6. PubMed ID: 8684394
[TBL] [Abstract][Full Text] [Related]
17. Levodopa effect upon functional balance of Parkinson's disease patients.
Nova IC; Perracini MR; Ferraz HB
Parkinsonism Relat Disord; 2004 Oct; 10(7):411-5. PubMed ID: 15465397
[TBL] [Abstract][Full Text] [Related]
18. Speech dysfunction in early Parkinson's disease.
Stewart C; Winfield L; Hunt A; Bressman SB; Fahn S; Blitzer A; Brin MF
Mov Disord; 1995 Sep; 10(5):562-5. PubMed ID: 8552106
[TBL] [Abstract][Full Text] [Related]
19. Effect of levodopa on pain threshold in Parkinson's disease: a clinical and positron emission tomography study.
Brefel-Courbon C; Payoux P; Thalamas C; Ory F; Quelven I; Chollet F; Montastruc JL; Rascol O
Mov Disord; 2005 Dec; 20(12):1557-63. PubMed ID: 16078219
[TBL] [Abstract][Full Text] [Related]
20. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
